Phytopharm plc is a development stage pharmaceutical Group developing novel treatments targeting diseases with high levels of unmet need, with the objective of developing products to key value inflection
points before seeking late-stage development and/or commercial partners, as appropriate.

Phytopharm operates as a virtual Group ensuring the majority of our financial resources are focussed on the development our pharmaceutical pipeline. We utilise a network of external scientific and clinical experts to help
guide our development programmes with our experienced pharmaceutical managers overseeing operations.

At the request of the Company, trading in Phytopharm's Premium listed shares on the Main Market of the London Stock Exchange has been suspended. Please see the press release below.